Advaxis (OTCMKTS:ADXS) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Advaxis (OTCMKTS:ADXS – Get Rating) in a research note issued to investors on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Shares of ADXS opened at $0.10 on Monday. The company has a 50 day moving average price of $0.11 and a 200-day moving average price of $0.24. Advaxis has a fifty-two week low of $0.08 and a fifty-two week high of $0.76. The stock has a market capitalization of $14.53 million, a PE ratio of -1.00 and a beta of 2.07.

Advaxis (OTCMKTS:ADXS – Get Rating) last posted its earnings results on Thursday, March 17th. The biotechnology company reported ($0.03) EPS for the quarter.

A number of large investors have recently bought and sold shares of ADXS. Geode Capital Management LLC raised its holdings in shares of Advaxis by 10.5% during the third quarter. Geode Capital Management LLC now owns 1,135,533 shares of the biotechnology company’s stock worth $592,000 after purchasing an additional 108,116 shares during the last quarter. Millennium Management LLC purchased a new position in Advaxis in the third quarter valued at $128,000. GSA Capital Partners LLP purchased a new position in Advaxis in the third quarter valued at $80,000. Morgan Stanley increased its holdings in Advaxis by 127.3% in the second quarter. Morgan Stanley now owns 107,282 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 60,075 shares in the last quarter. Finally, Advisor Group Holdings Inc. increased its holdings in Advaxis by 4,394.3% in the third quarter. Advisor Group Holdings Inc. now owns 79,954 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 78,175 shares in the last quarter. 6.72% of the stock is owned by institutional investors.

About Advaxis (Get Rating)

Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.

Featured Articles